"Authorized" Generics Will Be Subject To "Best Price" Calculations, CMS Suggests

Letter to GPhA from agency says that the products are considered innovator multiple source drugs, which would discourage the use of the practice by brand firms. CMS says it is reviewing its policy on calculation of prices for such products.